Tesamorelin peptide is also known as:
- Egrifta
- Tesamorelin acetate
- hGH-releasing peptide
- Synthetic growth hormone-releasing hormone (GHRH)
It is a synthetic form of GHRH, which is a naturally occurring hormone that stimulates the release of growth hormone from the pituitary gland. Growth hormone plays an important role in body growth and development, as well as in metabolism and body composition.
Tesamorelin is used to reduce excess visceral fat (belly fat) in HIV-infected individuals with lipodystrophy. Lipodystrophy is a condition that causes changes in the way body fat is distributed in people with HIV infection. People with HIV lipodystrophy may have too much fat in their abdomen and upper back, and too little fat in their arms, legs, and face.
Tesamorelin is also being investigated for the treatment of a number of other conditions, including:
- Obesity
- Growth hormone deficiency
- Cachexia (a wasting condition that can occur with cancer or other chronic diseases)
- Frailty in older adults
Tesamorelin is given by injection under the skin (subcutaneously) once a day. It is generally well-tolerated, but some people may experience side effects such as headache, dizziness, nausea, and injection site reactions. Tesamorelin is not recommended for pregnant or breastfeeding women.
Here are some additional things to know about tesamorelin peptide:
- It is a relatively new drug, having been approved by the FDA in 2010.
- It is a prescription drug and is not available over-the-counter.
- It is covered by some insurance plans, but it may not be covered by all plans.
- It is important to talk to your doctor about the risks and benefits of tesamorelin peptide before starting treatment.
If you are interested in learning more about tesamorelin peptide, I recommend that you consult with a healthcare professional.
